Mechanism of PARP inhibitor resistance and potential overcoming strategies

PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing the DNA single-strand break repair process. Despite the significant therapeutic effect in patients with homologous r...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Xiaoyu, Li, Ping, Zhou, Qi, He, Ruyuan, Wang, Guannan, Zhu, Shiya, Bagheri, Amir, Kupfer, Gary, Pei, Huadong, Li, Juanjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425807/
https://www.ncbi.nlm.nih.gov/pubmed/37588193
http://dx.doi.org/10.1016/j.gendis.2023.02.014
_version_ 1785089920407175168
author Fu, Xiaoyu
Li, Ping
Zhou, Qi
He, Ruyuan
Wang, Guannan
Zhu, Shiya
Bagheri, Amir
Kupfer, Gary
Pei, Huadong
Li, Juanjuan
author_facet Fu, Xiaoyu
Li, Ping
Zhou, Qi
He, Ruyuan
Wang, Guannan
Zhu, Shiya
Bagheri, Amir
Kupfer, Gary
Pei, Huadong
Li, Juanjuan
author_sort Fu, Xiaoyu
collection PubMed
description PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing the DNA single-strand break repair process. Despite the significant therapeutic effect in patients with homologous recombination (HR) repair deficiency, innate and acquired resistance to PARPi is a main challenge in the clinic. In this review, we mainly discussed the underlying mechanisms of PARPi resistance and summarized the promising solutions to overcome PARPi resistance, aiming at extending PARPi application and improving patient outcomes.
format Online
Article
Text
id pubmed-10425807
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Chongqing Medical University
record_format MEDLINE/PubMed
spelling pubmed-104258072023-08-16 Mechanism of PARP inhibitor resistance and potential overcoming strategies Fu, Xiaoyu Li, Ping Zhou, Qi He, Ruyuan Wang, Guannan Zhu, Shiya Bagheri, Amir Kupfer, Gary Pei, Huadong Li, Juanjuan Genes Dis Review Article PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing the DNA single-strand break repair process. Despite the significant therapeutic effect in patients with homologous recombination (HR) repair deficiency, innate and acquired resistance to PARPi is a main challenge in the clinic. In this review, we mainly discussed the underlying mechanisms of PARPi resistance and summarized the promising solutions to overcome PARPi resistance, aiming at extending PARPi application and improving patient outcomes. Chongqing Medical University 2023-03-24 /pmc/articles/PMC10425807/ /pubmed/37588193 http://dx.doi.org/10.1016/j.gendis.2023.02.014 Text en © 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review Article
Fu, Xiaoyu
Li, Ping
Zhou, Qi
He, Ruyuan
Wang, Guannan
Zhu, Shiya
Bagheri, Amir
Kupfer, Gary
Pei, Huadong
Li, Juanjuan
Mechanism of PARP inhibitor resistance and potential overcoming strategies
title Mechanism of PARP inhibitor resistance and potential overcoming strategies
title_full Mechanism of PARP inhibitor resistance and potential overcoming strategies
title_fullStr Mechanism of PARP inhibitor resistance and potential overcoming strategies
title_full_unstemmed Mechanism of PARP inhibitor resistance and potential overcoming strategies
title_short Mechanism of PARP inhibitor resistance and potential overcoming strategies
title_sort mechanism of parp inhibitor resistance and potential overcoming strategies
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425807/
https://www.ncbi.nlm.nih.gov/pubmed/37588193
http://dx.doi.org/10.1016/j.gendis.2023.02.014
work_keys_str_mv AT fuxiaoyu mechanismofparpinhibitorresistanceandpotentialovercomingstrategies
AT liping mechanismofparpinhibitorresistanceandpotentialovercomingstrategies
AT zhouqi mechanismofparpinhibitorresistanceandpotentialovercomingstrategies
AT heruyuan mechanismofparpinhibitorresistanceandpotentialovercomingstrategies
AT wangguannan mechanismofparpinhibitorresistanceandpotentialovercomingstrategies
AT zhushiya mechanismofparpinhibitorresistanceandpotentialovercomingstrategies
AT bagheriamir mechanismofparpinhibitorresistanceandpotentialovercomingstrategies
AT kupfergary mechanismofparpinhibitorresistanceandpotentialovercomingstrategies
AT peihuadong mechanismofparpinhibitorresistanceandpotentialovercomingstrategies
AT lijuanjuan mechanismofparpinhibitorresistanceandpotentialovercomingstrategies

Ejemplares similares